CytoMed Therapeutics Limited (GDTC) has released an update.

CytoMed Therapeutics Limited has expanded its biopharmaceutical focus on cell-based therapies by acquiring a Malaysian cord blood banking license and corresponding assets, including cryopreservation equipment and cord blood units. The move, through its subsidiary LongevityBank, aims to leverage the therapeutic potential of cord blood in regenerative medicine and diseases related to aging. The strategic acquisition signals CytoMed’s intent to further delve into cell therapies for longevity and wellness, with a vision for future specialization in umbilical cord blood-derived cell therapy.

For further insights into GDTC stock, check out TipRanks’ Stock Analysis page.